Silence Therapeutics plc

Silence Therapeutics plc is a clinical-stage biotechnology company dedicated to discovering and developing novel medicines that utilize short interfering ribonucleic acid (siRNA) therapeutics. The company's core mission is to transform lives globally by silencing disease-associated genes through precision-engineered medicines, leveraging its proprietary mRNAi GOLD™ platform. Headquartered in London, United Kingdom, with additional offices in New Jersey, USA, and Berlin, Germany, Silence Therapeutics focuses on addressing unmet medical needs across various therapeutic areas.

The company's development pipeline includes several siRNA product candidates targeting specific disease areas. Key programs include Divesiran (SLN124), which is in development for polycythemia vera and other hematological conditions, and Zerlasiran (SLN360), aimed at reducing cardiovascular risk in individuals with high lipoprotein(a). Other pipeline candidates include SLN548 for complement-mediated diseases and SLN312. Silence Therapeutics primarily focuses its research and development efforts on hematology, cardiovascular diseases, and rare diseases.

In terms of recent developments, Iain Ross serves as the Interim Principal Executive Officer and Chairman, having assumed the role in December 2025. The company announced positive topline results in August 2026 from its Phase 2 SANRECO trial for divesiran in polycythemia vera, demonstrating an 88% clinical response rate, with a Phase 3 trial planned for the first half of 2027. Additionally, Silence Therapeutics successfully closed an upsized public offering in August 2026, raising approximately $175 million to support its pipeline advancements.